"Pharmaceutical Composition of a Recombinant Adeno-Associated Virus Vector and its Application" in Patent Application Approval Process (USPTO 20240165177).
In: Gene Therapy Weekly, 2024-06-11, S. 2086-2086
serialPeriodical
Zugriff:
The patent application by Sichuan Real&Best Biotech Co. Ltd. outlines a pharmaceutical composition for a recombinant adeno-associated virus (rAAV) vector used in gene therapy. The composition includes specific components such as salts, buffers, stabilizers, and surfactants. The rAAV vector has been proven effective in targeting genes in different tissues and the composition is designed to remain stable for over a year under refrigeration. The patent application provides detailed information on the components and concentrations used in the composition. For further details, please refer to the complete patent application. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Pharmaceutical Composition of a Recombinant Adeno-Associated Virus Vector and its Application" in Patent Application Approval Process (USPTO 20240165177).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-06-11, S. 2086-2086 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|